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INTRODUCTION
One of the main directions in the development 
of modern science and medicine is the molecular 
genetic study of endogenous/genetic factors, which 
lead to the disease.[1] Among the significant number 
of approaches in the study of genetic susceptibility 
to various pathologies, the search for associations 
of polymorphic genetic loci with disease is widely 
used.[1-7]
Chronic glomerulonephritis (CGN) is an immune 
complex kidney disease with predominant lesion of 
the renal glomeruli, leading to progressive death of 
glomeruli, hypertension, and renal failure.[8] Majority 
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of patients with glomerulonephritis have CGN;[9] 
their quantity far exceeds the number of people with 
acute glomerulonephritis. CGN can be either the 
consequence of acute nephritis or can be primarily 
chronic. The prevalence of this renal pathology is 
steadily increasing worldwide.[10] Therefore, the issue 
of identifying criteria, which allow to evaluate the 
prognosis of clinical course and treatment of CGN, is 
highly relevant.
According to the modern literature sources, 
cytokines play an important role in the development 
of renal pathologies, including CGN. They have 
a leading role in the pathogenesis of immune 
inflammation.[11,12] Cytokines are low-molecular 
peptides, produced by cells. They perform short-
distance regulation of intercellular and intersystem 
interactions, which determine cell survival, 
stimulation and inhibition of their growth, functional 
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activity, and apoptosis of cells.[13,14] Some sources 
emphasized the role of tumor necrosis factor (TNF) 
alpha, TNF receptor, and transforming growth factor 
β1 in the pathogenesis of CGN.[15-17] In this regard, 
cytokine genes can be considered as candidate genes 
of CGN.[18]
It is worth noting that, despite the significant amount 
of work, aimed at studying the treatment of patients 
with CGN, this issue remains highly relevant and 
quite controversial. Special attention should be paid 
to glucocorticoid therapy, which has a pronounced 
anti-inflammatory and immunosuppressive effect.[19] 
Moreover, the use of these drugs also changes the 
course of glomerulonephritis.
Thus, the purpose of this study is to evaluate the 
effectiveness of glucocorticoid therapy in patients 
with CGN, depending on the polymorphic cytokine 
loci rs1800629 TNFα, rs909253 Ltα, rs767455 
TNFR1, and rs1800469 TGFβ-1.
MATERIALS AND METHODS
The analysis of polymorphic cytokine loci was carried out 
among 370 people: 202 patients with CGN (average age 
41.08 ± 13.97 years) and 168 people in the control group 
(average age 42.20 ± 6.28 years, P > 0.05). The studied 
groups consisted of the individuals of Russian nationality, 
who were natives of the Central Black Earth Region 
of Russia, and were not related to each other. Patients 
were included in the certain group only after making 
the diagnosis, confirmed by clinical and laboratory-
instrumental methods of examination, by the staff of the 
Nephrology Department of St. Joseph Belgorod Regional 
Clinical Hospital. The studied groups of patients with 
CGN and control group are comparable by gender, age 
characteristics, place of birth, and nationality.
Venous blood in a volume of 8–9 ml, taken from the 
ulnar vein of the proband, was the material for the 
study. Genomic DNA was extracted from peripheral 
blood using standard methods.[20]
Genotyping of DNA markers (rs1800629 TNFα, 
rs909253 Ltα, rs767455 TNFR1, and rs1800469 
TGFβ-1) was performed by the method of 
polymorphism analysis of the length of restriction 
fragments of PCR amplification products of specific 
genome regions, using appropriate restriction enzymes.
The study of therapy efficiency (medication with 
glucocorticoids, cytostatics, and angiotensin-converting 
enzyme inhibitors) was conducted among 169 patients 
with CGN (79 men and 90 women). The average age 
of patients was 36.2 ± 8.9 years; the duration of disease 
was 7.4 ± 5.6 years. In this research, homozygotes 
by pro-inflammatory and fibroblastic alleles were 
combined into one group with heterozygotes.
The research materials were processed by statistical 
methods, using the program Statistica 8.0. The 
criterion cChi-square was applied with the aim to 
analyze the compliance of the observed distribution 
of genotypes with the expected, based on the Hardy–
Weinberg equilibrium. In the process of comparative 
analysis of the frequencies of alleles and genotypes of 
the studied loci between the control and case groups 
of patients, the Chi-square criterion was used, with 
Yates correction for continuity. The calculations 
were performed in 2×2 contingency tables. Statistical 
differences were considered significant when P < 0.05.
RESULTS AND DISCUSSION
All patients with CGN (202 people) and the individuals 
of the control group (168 people) received typing of 
four molecular genetic markers of cytokines: TNFα 
(rs1800629 TNFα), lymphotoxin α (rs909253 Ltα), 
TNF receptor (rs767455 TNFR1), and transforming 
growth factor β1 (rs1800469 TGFβ-1). The inclusion 
of the above genetic polymorphisms in the analysis 
is due to the pathogenetic significance of cytokines, 
determining by them, for CGN.
The investigation of genotype frequencies of 
polymorphic gene markers showed that for all the 
considered markers in the control group and for 
most markers in the group of patients with CGN, the 
empirical distribution of genotypes corresponds to the 
theoretically expected at Hardy–Weinberg equilibrium 
(P > 0.05) [Table 1]. However, among patients with 
Table 1: Summary information about the studied polymorphisms
SNP Studied groups Minor allele MAF (%) HWE
χ2 P
rs1800629 TNFα
rs1800629 TNFα
Case
Control
A
A
16.25
11.64
6.83
0.43
>0.05 >0.05
rs909253 Ltα
rs909253 Ltα
Case
Control
G
G
27.92
30.95
0.87
0.15
>0.05 >0.05
rs767455 TNFR1
rs767455 TNFR1
Case
Control
G
G
45.71
54.48
11.10
0.98
<0.01 >0.05
rs1800469 TGFβ-1
rs1800469 TGFβ-1
Case
Control
T
T
42.96
38.34
0.89
1.72
>0.05 >0.05
MAF: Minor allele frequency, HWE: Hardy–Weinberg equilibrium. P values were calculated using the Chi-square test
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CGN, there was a deviation from Hardy–Weinberg 
equilibrium for the locus TNFR1 (rs767455), due 
to a decrease in actual heterozygosity, compared to 
theoretical (χ2 = 11.10, P < 0.01), as evidenced by 
negative values of fixation index (D = −0.23).
Comparative analysis of the frequencies of alleles 
and genotypes of the studied loci among patients with 
CGN and the control group did not reveal statistically 
significant differences (P > 0.05).
At the next stage of work, the investigation was 
conducted on the effectiveness of glucocorticoid 
therapy in patients with CGN (n = 42), depending on 
the polymorphic cytokine loci [Table 2]. It has been 
established that among patients with CGN, with non-
inflammatory allele A (AA genotype) of lymphotoxin 
α gene (rs909253) and allele G of the TNF receptor 
gene (rs767455) (GG genotype), the proportion of 
patients with steroid-sensitive nephrotic syndrome is 
significantly higher, compared to individuals with pro-
inflammatory alleles of these genes: For lymphotoxin 
α gene – 73.1% and 50.0%, respectively, (P < 0.01) 
and for the TNF receptor gene – 90.0% and 53.1%, 
respectively (P < 0.001) [Table 2]. As for other analyzed 
genes (rs1800629 TNFα and rs1800469 TGFβ-1), 
there were no significant differences in the proportion 
of steroid-sensitive patients, among people with pro-
inflammatory and non-inflammatory genotypes. In 
case of combination of non-inflammatory alleles of 
lymphotoxin α genes and the TNF receptor in the 
genotype, the proportion of steroid-sensitive patients 
is 88.2%, that is, almost 3 times higher than the similar 
indicator for patients with pro-inflammatory alleles of 
these genes – 33.3% (P < 0.001).
According to literature data,[21] individuals with “wild” 
(non-inflammatory) alleles of cytokine genes have 
reduced levels of cytokines. In patients with CGN, 
they are effectively suppressed by the administration 
of glucocorticoids. Medicinal preparations, belonging 
to this group, and used for the treatment of CGN, 
have a pronounced immunosuppressive and anti-
inflammatory effect.[19] However, in case of elevated 
concentrations of cytokines observed according to 
Karplus et al., 2002,[22] in individuals with mutant (pro-
inflammatory) alleles of cytokine genes, monotherapy 
for the arresting of CGN exacerbation is insufficient, 
and simultaneous administration of glucocorticoids 
and cytostatics is required (combined therapy). In this 
case, the joint pathogenetic action of drugs, belonging 
to these groups, is more pronounced – they produce 
anti-inflammatory and immunosuppressive effects, 
and that ultimately provides a positive therapeutic 
outcome in the process of CGN treatment.
It should be noted that the data obtained are important 
for practical nephrology because molecular genetic 
typing of loci rs1800629 TNFα, rs909253 Ltα, 
rs767455 TNFR1, and rs1800469 TGFβ-1 in patients 
with CGN will allow not only to identify groups 
of patients with a poor prognosis of CGN (early 
development of chronic renal failure, end stage of 
chronic renal failure, etc.) but also to determine a 
more optimal strategy for CGN treatment.
CONCLUSION
Thus, in the framework of this work, the investigation 
of the effectiveness of glucocorticoid therapy 
was conducted. It was performed depending on 
the polymorphic cytokine loci (rs1800629 TNFα, 
rs909253 Ltα, rs767455 TNFR1, and rs1800469 
TGFβ-1), in patients with CGN, who are the residents 
of the Central Black Earth Region of Russia. It has 
been established that in patients with CGN, which 
have pro-inflammatory gene alleles of lymphotoxin 
α (rs909253 Ltα) and the TNF receptor (rs767455 
Table 2: Effects of glucocorticoid therapy, depending on polymorphic cytokine loci
SNP Genotypes The effectiveness of therapy (%)
Steroid‑sensitive nephrotic 
syndrome (n=27)
Steroid‑resistant nephrotic 
syndrome (n=15)
rs1800629 TNFα GG 62.5 37.5
GA, AA 70.0 30.0
χ2 0.81
P P>0.05
rs909253 Ltα GG, AG 50.0 50.0
AA 73.1 26.9
χ2 10.22
P P<0.01
rs767455 TNFR1 AA, AG 53.1 46.9
GG 90.0 10.0
χ2 31.80
Р P<0.001
rs1800469 TGFβ-1 CC 61.5 38.5
ТС, TT 65.5 34.5
χ2 0.09
P P>0.05
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TNFR1); glucocorticoid therapy is not very effective 
(only 10–30% of these patients are steroid sensitive). 
In case of non-inflammatory alleles of these genes, the 
efficiency of hormone therapy is maximum: Steroid-
sensitive nephrotic syndrome is observed in 73–90% 
of patients.
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